Symphogen is the Antibody Center of Excellence within the Servier Group, a global pharmaceutical group dedicated to improving patients' health. With a highly efficient antibody platform, Symphogen specializes in the discovery and early development of differentiated antibody therapeutics. As part of the Servier Group, Symphogen supports their R&D strategy in the fields of oncology and immune oncology.

Founded in 2000, Symphogen has a team of passionate and dedicated professionals who strive to make unique discoveries. With the backing of Servier, a foundation governed group with a strong international presence, Symphogen has the resources and expertise to drive therapeutic innovation. In line with Servier's commitment to open and collaborative innovation, Symphogen actively engages with academic partners, pharmaceutical groups, and biotech companies.

By integrating the patient's voice throughout the research and development process, Symphogen ensures that their antibody therapeutics address the real needs of patients. For more information about Symphogen and their novel antibody therapeutics, please visit their website